TY - JOUR
T1 - Clinical utility of immunohistochemistry for the detection of the BRAF v600e mutation in papillary thyroid carcinoma
AU - Zagzag, Jonathan
AU - Pollack, Aron
AU - Dultz, Linda
AU - Dhar, Shumon
AU - Ogilvie, Jennifer B.
AU - Heller, Keith S.
AU - Deng, Fang Ming
AU - Patel, Kepal N.
N1 - Funding Information:
Supported by the NYUCI Center Support Grant NIH/NCI 5 P30CA16087-31 . This project was funded in whole or in part by the National Institutes of Health's National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program (CTSA), grant UL1 TR000038 .
PY - 2013/12
Y1 - 2013/12
N2 - Background BRAF V600E mutation is the most common genetic alteration in papillary thyroid cancer (PTC). We used a mutation-specific antibody for immunohistochemical (IHC) detection of the BRAF V600E mutation and correlated expression with clinicopathologic features. The study was designed to validate the accuracy and determine the clinical importance of IHC detection of the BRAF V600E mutation in PTC. Methods Direct sequencing and IHC for BRAF V600E mutation was performed in 37 consecutive patients with PTCs. IHC was scored on an intensity proportion scale. IHC positive tumors were stratified into intensity categories. The categories were assessed for clinicopathologic variables, including age, extrathyroidal extension, lymphovascular invasion, and lymph node metastases. Results A total of 25 PTCs were BRAF V600E-positive and 12 were BRAF mutation-negative on IHC. The BRAF V600E mutation-specific antibody had a sensitivity of 89% and specificity of 100% for detecting the mutation. Tumors with high-intensity staining were more likely to have extrathyroidal extension. Conclusion IHC is an accurate method for the detection of the BRAF V600E mutation in PTC, and its ability to quantify the mutation expression may serve as a better predictor of tumor behavior than molecular sequencing. It provides a potentially rapid, easily applicable, and economic alternative to current techniques.
AB - Background BRAF V600E mutation is the most common genetic alteration in papillary thyroid cancer (PTC). We used a mutation-specific antibody for immunohistochemical (IHC) detection of the BRAF V600E mutation and correlated expression with clinicopathologic features. The study was designed to validate the accuracy and determine the clinical importance of IHC detection of the BRAF V600E mutation in PTC. Methods Direct sequencing and IHC for BRAF V600E mutation was performed in 37 consecutive patients with PTCs. IHC was scored on an intensity proportion scale. IHC positive tumors were stratified into intensity categories. The categories were assessed for clinicopathologic variables, including age, extrathyroidal extension, lymphovascular invasion, and lymph node metastases. Results A total of 25 PTCs were BRAF V600E-positive and 12 were BRAF mutation-negative on IHC. The BRAF V600E mutation-specific antibody had a sensitivity of 89% and specificity of 100% for detecting the mutation. Tumors with high-intensity staining were more likely to have extrathyroidal extension. Conclusion IHC is an accurate method for the detection of the BRAF V600E mutation in PTC, and its ability to quantify the mutation expression may serve as a better predictor of tumor behavior than molecular sequencing. It provides a potentially rapid, easily applicable, and economic alternative to current techniques.
UR - http://www.scopus.com/inward/record.url?scp=84887995180&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84887995180&partnerID=8YFLogxK
U2 - 10.1016/j.surg.2013.06.020
DO - 10.1016/j.surg.2013.06.020
M3 - Article
C2 - 23931769
AN - SCOPUS:84887995180
SN - 0039-6060
VL - 154
SP - 1199
EP - 1205
JO - Surgery (United States)
JF - Surgery (United States)
IS - 6
ER -